The Janus of lupus--benefits and risks with B-cell therapy. - Wikidata - awgldk - TriplyDB

The Janus of lupus--benefits and risks with B-cell therapy.

The Janus of lupus--benefits and risks with B-cell therapy.

http://www.wikidata.org/entity/Q37168037

about

Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases.

P2860

Q37541561-971DB7CF-EAA1-4B83-80AB-29391FEF64AD

P2860

The Janus of lupus--benefits and risks with B-cell therapy.

http://www.wikidata.org/entity/Q37168037

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The Janus of lupus--benefits and risks with B-cell therapy.

@en

The Janus of lupus--benefits and risks with B-cell therapy.

@nl

type

label

The Janus of lupus--benefits and risks with B-cell therapy.

@en

The Janus of lupus--benefits and risks with B-cell therapy.

@nl

prefLabel

The Janus of lupus--benefits and risks with B-cell therapy.

@en

The Janus of lupus--benefits and risks with B-cell therapy.

@nl

P1433

Q37168037-34049D9B-23ED-4DDC-AE3B-0642E5F9A084

P1476

Q37168037-045FD173-0634-4C09-BDE7-E0C857628136

P2093

Q37168037-E652FF0B-022B-4514-A930-E80D765DB385

P2860

Q37168037-0B944324-4CF9-43E8-809B-9566AE0CD7B9

Q37168037-0FBD659C-FC1E-4DD4-A4B7-7DAF560859D2

Q37168037-0FC8AA81-C98F-404B-BF08-45FCE25EEAF1

Q37168037-33D06E5E-3350-4098-A93B-2AB2D6D6A7F6

Q37168037-4054CCCB-1D37-4023-B81A-3C2EBBBECB9D

Q37168037-71BCF398-EFF9-40E2-9D04-5D98D77ABFE5

Q37168037-8DB4A951-FD16-45C7-A9F7-B217DDCB2164

Q37168037-9D31C375-677D-4352-8FC7-DCF906A3EABD

Q37168037-A48F53AA-9F58-43CD-9A30-589C39704D6E

Q37168037-A99C5414-267C-47E0-8590-4E03D4FCB979

P304

Q37168037-4D8CBDA9-F4E1-4D17-BB67-0A7D31A5F71F

P31

Q37168037-E7EFAC0E-FBBC-4F5B-842F-B61BB12274F4

P356

Q37168037-B5B6B59B-47FD-48C1-85E2-1356961CF227

P433

Q37168037-23F2269A-7335-4BFA-B20F-4AC62EE360A8

P478

Q37168037-649CA998-81BB-4231-9408-E5E5752A44BA

P577

Q37168037-2E887964-7225-4FAA-82D3-A04B3DE075ED

P698

Q37168037-6D044683-69D6-405A-9625-5D3E77A8EC27

P356

0961203308090033

P1433

P1476

The Janus of lupus--benefits and risks with B-cell therapy.

@en

P2093

R F van Vollenhoven

http://www.w3.org/2001/XMLSchema#string

P2860

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease.

Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

Tolerability and safety of rituximab (MabThera).

Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab.

B-cell-targeted therapy for systemic lupus erythematosus.

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

An open study of B lymphocyte depletion in systemic lupus erythematosus.

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.

P304

447-449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0961203308090033

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18490425

http://www.w3.org/2001/XMLSchema#string